We have located links that may give you full text access.
Predictors of hernia recurrence after Rives-Stoppa repair in the treatment of incisional hernias: a retrospective cohort.
Surgical Endoscopy 2019 September
BACKGROUND: Rives-Stoppa retromuscular repair (RSR) has been traditionally used to provide adequate coverage for large abdominal wall defects and appears to be more advantageous compared to other surgical techniques concerning complications and recurrence rates. The aim of this study was to identify the independent predictors associated to hernia recurrence after RSR in the treatment of incisional hernias.
METHODS: This is a retrospective observational study of 213 patients who underwent RSR between June 2007 and January 2014 at a tertiary centre. Main inclusion criteria were adults with midline hernia classified as M1, M2, M3, M4, or M5, according to EHS classification. All the cases presented a transverse hernia defect measurement greater than 5 cm (grades W2 and W3). Recurrence rate was determined by clinical examination plus confirmation by abdominal CT scan.
RESULTS: At a median of 57.6 months (range 46-75 months) of postoperative follow-up, we reported 15 cases of recurrence (7.1%). Recurrences occurred after a mean period of 19.4 months (range 2-49 months). On multivariate analysis, steroid or immunosuppressive drugs use (OR 2.02; CI 1.16-3.95, p = 0.004), the development of postoperative hematoma (OR 2.9; CI 1.55-4.10, p = 0.001), and needing surgery for the hematoma (OR 2.1; CI 1.21-3.29, p = 0.004) were predictors of recurrence after RSR. There was no significant difference in recurrence rate among obesity, smoking, urgent repair, type of mesh fixation, operative time, type of prosthesis, or concomitant procedures.
CONCLUSIONS: In our current study, using immunosuppressive drugs, the development of postoperative hematoma and needing surgery for the hematoma were associated with increased risk of hernia recurrence after RSR.
METHODS: This is a retrospective observational study of 213 patients who underwent RSR between June 2007 and January 2014 at a tertiary centre. Main inclusion criteria were adults with midline hernia classified as M1, M2, M3, M4, or M5, according to EHS classification. All the cases presented a transverse hernia defect measurement greater than 5 cm (grades W2 and W3). Recurrence rate was determined by clinical examination plus confirmation by abdominal CT scan.
RESULTS: At a median of 57.6 months (range 46-75 months) of postoperative follow-up, we reported 15 cases of recurrence (7.1%). Recurrences occurred after a mean period of 19.4 months (range 2-49 months). On multivariate analysis, steroid or immunosuppressive drugs use (OR 2.02; CI 1.16-3.95, p = 0.004), the development of postoperative hematoma (OR 2.9; CI 1.55-4.10, p = 0.001), and needing surgery for the hematoma (OR 2.1; CI 1.21-3.29, p = 0.004) were predictors of recurrence after RSR. There was no significant difference in recurrence rate among obesity, smoking, urgent repair, type of mesh fixation, operative time, type of prosthesis, or concomitant procedures.
CONCLUSIONS: In our current study, using immunosuppressive drugs, the development of postoperative hematoma and needing surgery for the hematoma were associated with increased risk of hernia recurrence after RSR.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app